公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2011 | Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells | Chen, KF; Chen, HL; Tai, WT; Feng, WC; Hsu, CH; Chen, PJ; Cheng, AL | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | | | |
2006 | Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma | Cheng, TY; Lin, JT; Chen, LT; Shun, CT; Wang, HP; Lin, MT; Wang, TE; Cheng, AL; Wu, MS | Journal of Clinical Oncology | | | |
2016 | Comparisons of genetic alterations of breast cancer between East and West: Special emphases on young patients with ER /HER2tumors | CHIU-HSUN LIN; Lu, TP; RUBY YUN-JU HUANG ; Lu, YS; Lo, KY; Kuo, KT; Chuang, EY; Wu, PF; Chen, IC; Thiery, JP; Huang, CS; Cheng, AL | CANCER RESEARCH | 0 | 0 | |
2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. | Lin, CC; Hsu, CH; Cheng, JC; Wang, HP; Lee, JM; Yeh, KH; Yang, CH; Lin, JT; Cheng, AL; Lee, YC. | Ann Oncol | | | |
2004 | Down-regulation of thymidyalte synthase expression and its steady-state messenger RNA by oxaliplatin in colon cancer cells. | Yeh, KH; Cheng, AL; Wan, JP; Lin, CS; Liu, CC. | Anti-Cancer Drugs | | | |
2016 | Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy | Chen, BB; Hsu, CY; Yu, CW; Liang, PC; Hsu, C; Hsu, CH; Cheng, AL; Shih, TTF | RADIOLOGY | | | |
2005 | Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. | Lu, YS; Lien, HC; Yeh, PY; Kun-Huei, Yeh; Kuo, ML; Kuo, SH; Cheng, AL | World J Gastroenterol | | | |
2000 | Intestinal microflora is improved by the feeding of an oligosaccharide containing soft drink in rats. | Cheng, AL; Pan, TM; Hung, HP; Huang, CJ | Nutr Sci J | | | |
2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | Kuo, SH; Hsu, CH; Chen, LT; Lu, YS; Lin, CH; Yeh, PY; Jeng, HJ; Gao, M; Yeh, KH; Cheng, AL | EUROPEAN JOURNAL OF CANCER | 0 | 0 | |
2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa, GK; Yen, CJ; Hsu, CH; O'Donoghue, J; Beylergil, V; Ruan, ST; Pandit-Taskar, N; Gansukh, B; Lyashchenko, SK; Ma, J; Wan, P; Shao, YY; Lin, ZZ; Frenette, C; O'Neil, B; Schwartz, L; Smith-Jones, PM; Ohtomo, T; Tanaka, T; Morikawa, H; Maki, Y; Ohishi, N; Chen, YC; Agajanov, T; Boisserie, F; Di Laurenzio, L; Lee, R; Larson, SM; Cheng, AL; Carrasquilo, JA | CANCER CHEMOTHERAPY AND PHARMACOLOGY | | | |
2008 | A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: A randomized trial. | Hsu, C; Hsiung, CA; Su, IJ; Hwang, WS; Wang, MC; Lin, SF; Lin, TH; Hsiao, HH; Young, JH; Chang, MC; Liao, YM; Li, CC; Wu, HB; Tien, HF; Cho, TY; Liu, TW; Cheng, AL; Chen, PJ | Hepatology | | | |
2005 | Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment. | Yang, CH; Chen, MC; Cheng, AL; Hsu, CH; Kun-Huei, Yeh; Yu, YC; Whang-Peng, J; Yang, PC. | Oncology | | | |
2006 | Treatment outcome and patterns of failure in breast cancer patients with locoregional recurrence after mastectomy | Kuo, SH; Cheng, JC; Huang, CS; Kuo, WH; Chien, CR; Ting, LL; Cheng, AL; Chang, KJ; Lai, MK | Therapeutic Radiology and Oncology | | | |